Literature DB >> 18058462

Downregulation of survivin is associated with reductions in TNF receptors' mRNA and protein and alterations in nuclear factor kappa B signaling in urothelial cancer cells.

Bayan T Takizawa1, Edward M Uchio, Justin J Cohen, Marcia A Wheeler, Robert M Weiss.   

Abstract

Because survivin is selectively expressed in and associated with an unfavorable prognosis in transitional cell carcinoma of the bladder (TCC), we treated T-24 cells with survivin siRNA. Survivin siRNA treatment caused a profound decrease of survivin protein that was associated with decreased cell growth, a specific G2/M arrest and increased cytochrome c release. Microarray analysis of apoptosis genes showed that levels of 14/114 gene products were decreased after 72 hours treatment with survivin siRNA, including survivin, three TNF receptors, Akt, c-Abl, caspases and their related genes and Bcl-2 and NF-kappaB signaling related genes. TNFR1, pro-caspase-2 and Akt protein levels were decreased after survivin siRNA treatment for 48 and 72 hours. Downregulation of survivin causes changes in mitosis and apoptosis, which may be related to changes in TNF receptors and NF-kappaB signaling.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 18058462     DOI: 10.1080/07357900701600954

Source DB:  PubMed          Journal:  Cancer Invest        ISSN: 0735-7907            Impact factor:   2.176


  8 in total

1.  siRNA directed against survivin enhances pancreatic cancer cell gemcitabine chemosensitivity.

Authors:  Wen-Song Liu; Hai-Jiao Yan; Ren-Yi Qin; Rui Tian; Min Wang; Jian-Xin Jiang; Ming Shen; Cheng-Jian Shi
Journal:  Dig Dis Sci       Date:  2008-07-02       Impact factor: 3.199

2.  Significance of survivin expression: Prognostic value and survival in stage III non-small cell lung cancer.

Authors:  Meng Wang; Bao-Gang Liu; Zhao-Yang Yang; Xuan Hong; Gong-Yan Chen
Journal:  Exp Ther Med       Date:  2012-03-12       Impact factor: 2.447

3.  Significance of survivin, caspase-3, and VEGF expression in thyroid carcinoma.

Authors:  Hai-Yan Zhang; Xin Meng; Zhen-Xian Du; Chang-Qing Fang; Guo-Liang Liu; Hua-Qin Wang; Wei-Wei Deng
Journal:  Clin Exp Med       Date:  2009-02-10       Impact factor: 3.984

4.  Survivin selectively modulates genes deregulated in human leukemia stem cells.

Authors:  Seiji Fukuda; Mariko Abe; Chie Onishi; Takeshi Taketani; Jamiyan Purevsuren; Seiji Yamaguchi; Edward M Conway; Louis M Pelus
Journal:  J Oncol       Date:  2010-12-23       Impact factor: 4.375

5.  Survivin modulates genes with divergent molecular functions and regulates proliferation of hematopoietic stem cells through Evi-1.

Authors:  S Fukuda; J Hoggatt; P Singh; M Abe; J M Speth; P Hu; E M Conway; G Nucifora; S Yamaguchi; L M Pelus
Journal:  Leukemia       Date:  2014-06-06       Impact factor: 11.528

6.  Combination of ERK2 inhibitor VX-11e and voreloxin synergistically enhances anti-proliferative and pro-apoptotic effects in leukemia cells.

Authors:  Ewa Jasek-Gajda; Halina Jurkowska; Małgorzata Jasińska; Jan A Litwin; Grzegorz J Lis
Journal:  Apoptosis       Date:  2019-12       Impact factor: 4.677

7.  Simultaneous siRNA-mediated knockdown of antiapoptotic BCL2, Bcl-xL, XIAP and survivin in bladder cancer cells.

Authors:  Doreen Kunze; Kai Kraemer; Kati Erdmann; Michael Froehner; Manfred P Wirth; Susanne Fuessel
Journal:  Int J Oncol       Date:  2012-07-06       Impact factor: 5.650

8.  Nanoparticles for urothelium penetration and delivery of the histone deacetylase inhibitor belinostat for treatment of bladder cancer.

Authors:  Darryl T Martin; Christopher J Hoimes; Hristos Z Kaimakliotis; Christopher J Cheng; Ke Zhang; Jingchun Liu; Marcia A Wheeler; W Kevin Kelly; Greg N Tew; W Mark Saltzman; Robert M Weiss
Journal:  Nanomedicine       Date:  2013-06-11       Impact factor: 5.307

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.